JP2025090691A5 - - Google Patents

Info

Publication number
JP2025090691A5
JP2025090691A5 JP2025037025A JP2025037025A JP2025090691A5 JP 2025090691 A5 JP2025090691 A5 JP 2025090691A5 JP 2025037025 A JP2025037025 A JP 2025037025A JP 2025037025 A JP2025037025 A JP 2025037025A JP 2025090691 A5 JP2025090691 A5 JP 2025090691A5
Authority
JP
Japan
Prior art keywords
seq
antibody
pharmaceutical formulation
antibody comprises
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2025037025A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025090691A (ja
Filing date
Publication date
Priority claimed from JP2022543445A external-priority patent/JP7674369B2/ja
Application filed filed Critical
Publication of JP2025090691A publication Critical patent/JP2025090691A/ja
Publication of JP2025090691A5 publication Critical patent/JP2025090691A5/ja
Pending legal-status Critical Current

Links

JP2025037025A 2020-01-24 2025-03-10 安定な抗体製剤 Pending JP2025090691A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062965786P 2020-01-24 2020-01-24
US62/965,786 2020-01-24
JP2022543445A JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤
PCT/US2021/014524 WO2021150829A1 (en) 2020-01-24 2021-01-22 Stable antibody formulation

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022543445A Division JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤

Publications (2)

Publication Number Publication Date
JP2025090691A JP2025090691A (ja) 2025-06-17
JP2025090691A5 true JP2025090691A5 (https=) 2025-07-15

Family

ID=74858743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022543445A Active JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤
JP2025037025A Pending JP2025090691A (ja) 2020-01-24 2025-03-10 安定な抗体製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2022543445A Active JP7674369B2 (ja) 2020-01-24 2021-01-22 安定な抗体製剤

Country Status (13)

Country Link
US (2) US12337199B2 (https=)
EP (1) EP4093435A1 (https=)
JP (2) JP7674369B2 (https=)
KR (1) KR20220131923A (https=)
CN (1) CN115243718A (https=)
AU (1) AU2021210942A1 (https=)
BR (1) BR112022014240A2 (https=)
CA (1) CA3162569A1 (https=)
CL (2) CL2022001989A1 (https=)
CO (1) CO2022010254A2 (https=)
IL (1) IL294375B1 (https=)
MX (1) MX2022008949A (https=)
WO (1) WO2021150829A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107635527B (zh) 2015-03-10 2021-04-23 里珍纳龙药品有限公司 无菌刺穿系统和方法
EP3487521A4 (en) 2016-07-21 2020-07-01 Emory University ANTIBODIES AGAINST EBOLA VIRUS AND LIAISON AGENTS DERIVED THEREFROM
KR102540409B1 (ko) 2017-05-05 2023-06-09 리제너론 파아마슈티컬스, 인크. 자동 주사기
USD1007676S1 (en) 2021-11-16 2023-12-12 Regeneron Pharmaceuticals, Inc. Wearable autoinjector
TW202529831A (zh) 2023-10-02 2025-08-01 美商再生元醫藥公司 藥物遞輸裝置安全系統
US12514939B2 (en) 2024-02-14 2026-01-06 Alpha-9 Oncology, Inc. Stable radiopharmaceutical compositions and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0747045B2 (ja) 1986-10-15 1995-05-24 株式会社大協精工 積層した注射器用滑栓
JP3100727B2 (ja) 1992-01-23 2000-10-23 株式会社大協精工 変性ポリシロキサン組成物及び該組成物を被覆した衛生ゴム製品
JP3172057B2 (ja) 1995-04-05 2001-06-04 株式会社大協精工 ラミネートゴム栓
JP3512349B2 (ja) 1999-01-29 2004-03-29 株式会社大協精工 柱状ゴム要素の成形型
US6630144B1 (en) 1999-08-30 2003-10-07 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies to Ebola glycoprotein
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
JP2002209975A (ja) 2001-01-19 2002-07-30 Daikyo Seiko Ltd 医薬バイアル用ラミネートゴム栓
US6875433B2 (en) 2002-08-23 2005-04-05 The United States Of America As Represented By The Secretary Of The Army Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
WO2009094755A1 (en) 2008-02-01 2009-08-06 Her Majesty The Queen In Right Of Canada As Represented By The Minister Of Health Monoclonal antibodies for ebola and marburg viruses
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
CA2741523C (en) 2008-10-24 2022-06-21 Jonathan S. Towner Human ebola virus species and compositions and methods thereof
ES2676205T3 (es) * 2011-03-31 2018-07-17 Merck Sharp & Dohme Corp. Formulaciones estables de anticuerpos para el receptor PD-1 humano de muerte programada y tratamientos relacionados
WO2014031718A1 (en) * 2012-08-23 2014-02-27 Merck Sharp & Dohme Corp. Stable formulations of antibodies to tslp
JP6041580B2 (ja) * 2012-08-28 2016-12-14 京セラ株式会社 電子機器、制御方法、及び制御プログラム
TWI710573B (zh) * 2015-01-26 2020-11-21 美商再生元醫藥公司 抗伊波拉病毒醣蛋白之人類抗體
TN2017000440A1 (en) 2015-04-17 2019-04-12 Bristol Myers Squibb Co Compositions comprising a combination of an anti-pd-1 antibody and another antibody
JP7402693B2 (ja) * 2017-05-02 2023-12-21 メルク・シャープ・アンド・ドーム・エルエルシー 単独のおよびプログラム死受容体1(pd-1)抗体と組み合わされた抗tigit抗体の安定な製剤、ならびにその使用方法
KR20210005096A (ko) * 2018-04-25 2021-01-13 메디뮨 리미티드 인간 항-pd-l1 항체의 제형

Similar Documents

Publication Publication Date Title
JP2025090691A5 (https=)
JP6396565B2 (ja) 抗インターロイキン−4受容体(il−4r)抗体を含有する安定化製剤
JP5608619B2 (ja) Tnf−アルファ関連疾患の治療用ヒト抗体の製剤
AU2013255413B2 (en) Pharmaceutical formulations of TNF-alpha antibodies
FI3606504T3 (fi) Stabiili vasta-aineformulaatio
JP2020518600A5 (https=)
TW201625221A (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
RU2006120950A (ru) Антитело к cd40: препарат и способы
IE57397B1 (en) Pharmaceutical compositions
JP2013543505A5 (https=)
CN113797333A (zh) 一种新型冠状病毒抗体的药物组合物及其用途
JP2003521518A (ja) モノチオグリセロール、l−システインまたはチオグリコール酸とともにペメトレクストを含む医薬組成物
WO2023186173A1 (zh) 包含针对狂犬病病毒g蛋白的双特异性抗体的药物制剂及其制备方法
JP2009521473A5 (https=)
EP3867271A1 (en) Formulations of anti-rsv antibodies and methods of use thereof
AR083338A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r)
NZ536178A (en) Epothilone derivative for the treatment of hepatoma and other cancer diseases
US20190183962A1 (en) Angiotensin compositions and methods related thereto
PT92163B (pt) Processo para a preparacao de uma composicao mdm liofilizada
JPS5933297A (ja) ウイルス感染症の予防及び治療剤
JPWO2023019171A5 (https=)
JPWO2023086817A5 (https=)
RU2016152691A (ru) Водная фармацевтическая композиция рекомбинантного моноклонального антитела к ФНОα
WO2008014431A2 (en) Method of treating ocular infections
JPWO2022231978A5 (https=)